ARCHIVES

Perjeta Neoadjuvant Therapy Granted Accelerated Approval In HER2 Breast Cancer

This article is from The Cancer Letter archive.

Vol. 36 No. 10 | October 25, 2013

Download PDF Visit The Full Archive

Related Articles

Only 20 Percent Of At-Risk Patients Are Screened For HBV Before Therapy

November 25, 2011

Advisors Voted For Provenge Approval Despite Fundamental Flaws In Trials.

April 13, 2007

Study: Blood Test More Accurate Than Traditional Tumor Biopsy

April 26, 2013

Search Committee Finishes Job, Submits Choices To Califano

April 15, 1977

Finasteride Does Not Affect Quality of Life, Says Study

September 28, 2012

IOM Panel Considering NCI Approach To Research In Minorities, Underserved

June 19, 1998